Last updated: February 13, 2026
What is NDC 72603-0157?
NDC 72603-0157 refers to a specific pharmaceutical product registered with the U.S. Food and Drug Administration (FDA). The National Drug Code (NDC) identifies this product, which is classified as a biologic or drug. Based on available public data, NDC 72603-0157 is identified as XELJANZ (tofacitinib) tablets, mainly used to treat rheumatoid arthritis and other autoimmune conditions.
How large is the current market for XELJANZ?
Market Size & Growth Trends
The rheumatoid arthritis (RA) treatment market is estimated at approximately USD 21 billion in 2023, with biologics making up more than 65% of treatment sales. JAK inhibitors, including tofacitinib (XELJANZ), captured a significant portion due to rapid adoption since their approval.
Market Share and Competitive Landscape
- XELJANZ: Has a 12% share of the RA biologics market, primarily competing with adalimumab, etanercept, and other JAK inhibitors like baricitinib.
- Competitors: Humira (adalimumab), Enbrel (etanercept), and Rinvoq (upadacitinib).
Key Drivers
- Rising prevalence of RA and other autoimmune diseases.
- Increasing adoption of oral therapies over injectables.
- Expanded indications, including psoriatic arthritis and ulcerative colitis.
Regional Dynamics
- U.S. accounts for approximately 70% of global RA biologics sales.
- Europe and Japan represent significant markets, with consistent growth trends.
What are the current pricing dynamics?
Wholesale Acquisition Cost (WAC)
- The average WAC for XELJANZ 5 mg tablets is approximately USD 1,800 per month per patient, based on ICER and SSR Health data (2023).
- Prices range from USD 1,700 to USD 2,000 per month depending on pharmacy discounts and insurance negotiations.
Reimbursement & Out-of-Pocket Costs
Insurance and pharmacy benefit managers negotiate rebates, lowering effective patient costs. The net price for manufacturers is typically 20–30% lower than WAC due to these rebates.
Pricing Comparison to Competitors
| Drug |
Price per Month |
Indications |
Market Share |
| XELJANZ (tofacitinib) |
USD 1,800 |
RA, PsA, UC |
12% |
| Humira (adalimumab) |
USD 3,600 |
RA, Crohn’s, UC, PsA |
35% |
| Rinvoq (upadacitinib) |
USD 2,200 |
RA, PsA |
8% |
XELJANZ remains relatively cost-effective compared to biologic injectables, which face higher administration costs and insurance barriers.
What are the future price projections?
Price Trajectory 2023–2028
- Stability in WAC: Prices are projected to remain stable or decline slightly (1–3%) annually owing to market competition and generic/biosimilar threats.
- Rebate trends: Growing rebate levels, averaging 25%, are expected to continue lowering net costs.
Impact of Patent Expiry and Biosimilar Competition
- Currently, patent expiry is not imminent; patent protections extend through 2027–2030.
- Entry of biosimilars could reduce prices, especially in Europe, by 15–25%.
Market Expansion and Revenue Potential
- Broadened indications could increase annual sales to USD 4–5 billion globally by 2028.
- Increased adoption in niche autoimmune indications could add USD 1 billion in revenue.
What are the key regulatory and policy factors affecting pricing?
- FDA approvals: Additional indications such as ulcerative colitis could boost utilization.
- Pricing regulations: Centers like ICER and value-based pricing initiatives could push for price reductions.
- Reimbursement policies: Changes in Medicare/Medicaid coverage could influence net revenue and patient access, potentially pressuring list prices.
Key Takeaways
- The current global RA biologics market exceeds USD 21 billion, with XELJANZ holding around 12% share.
- WAC for XELJANZ 5 mg tablets is approximately USD 1,800/month, with net prices declining due to rebates.
- Market growth depends on expanding indications, competition from biosimilars, and patient acceptance of oral therapies.
- Price stability is expected through 2028, barring biosimilar entrants; prices could decline 15–25% with biosimilar adoption in Europe.
- Revenue projections indicate that global sales could reach USD 4–5 billion by 2028.
FAQs
1. How does the pricing of XELJANZ compare to injectable biologics?
Oral XELJANZ costs roughly USD 1,800/month, while biologics like Humira are about USD 3,600/month, though rebates and insurance negotiations influence actual costs.
2. What factors could influence the price of XELJANZ in the next five years?
Patent expiration readiness, biosimilar entry, regulatory approvals for new indications, and policy shifts toward value-based pricing.
3. Are biosimilars likely to impact XELJANZ pricing?
While biosimilars mainly target injected biologics, market share could shift, especially in Europe, potentially reducing prices by 15–25%.
4. What is the estimated market growth for XELJANZ?
Sales could grow to USD 4–5 billion globally by 2028, driven by indication expansion and increasing autoimmune disease prevalence.
5. How does rebate influence the net price versus the WAC?
Rebates, averaging 20–30%, lower the net price paid by insurers and providers, often making the effective patient cost significantly less than the WAC.
Sources
- IQVIA, "Global Rheumatoid Arthritis Market Analysis," 2023.
- ICER Report, "Cost-effectiveness of Rheumatologic Drugs," 2023.
- SSR Health, "Prescription Data & Pricing Trends," 2023.
- FDA Label for XELJANZ, 2022.
- Pharma intelligence, "Biologic & Biosimilar Market Trends," 2023.
